Financial Performance - The company's operating revenue for Q3 2024 was ¥100,178,940.97, a decrease of 10.54% compared to the same period last year[2] - The net profit attributable to shareholders for Q3 2024 was ¥28,545,870.19, down 8.28% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥24,692,791.85, a decline of 2.88% compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 was CNY 291,757,867.37, a decrease of 12.06% compared to CNY 331,773,648.23 in the same period of 2023[14] - Net profit for the third quarter of 2024 was CNY 78,166,276.35, a decline of 23.14% from CNY 101,681,102.97 in the same quarter of 2023[15] - Basic earnings per share for the third quarter of 2024 was CNY 0.8221, compared to CNY 1.0660 in the same quarter of 2023, representing a decrease of 22.93%[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,775,404,170.42, a decrease of 1.70% from the end of the previous year[3] - The net assets attributable to shareholders were ¥1,612,218,560.02, down 0.89% from the previous year[3] - The company's total liabilities decreased to CNY 163,185,610.40 from CNY 179,268,822.19, a reduction of 8.96%[12] - The total amount of current liabilities was CNY 132,143,366.66, down from CNY 151,683,003.46, reflecting a decrease of 12.93%[12] - Current assets totaled CNY 1,137,050,969.30, down from CNY 1,254,828,009.43 in the previous period[11] Research and Development - Research and development expenses totaled ¥14,416,091.09, a decrease of 26.91% year-on-year, representing 14.39% of operating revenue[3] - Research and development expenses for the first three quarters of 2024 were CNY 39,929,327.90, a slight decrease from CNY 41,705,282.25 in the same period of 2023[14] - The company reported a significant increase in development expenditures, rising to CNY 21,574,007.39 from CNY 11,492,200.66[11] Cash Flow - The company’s cash flow from operating activities showed a positive trend, contributing to overall financial stability despite the decline in net profit[16] - Operating cash inflow for the first three quarters of 2024 was CNY 356,135,408.17, a decrease of 11.5% compared to CNY 402,479,751.93 in the same period of 2023[18] - Net cash flow from operating activities for the first three quarters of 2024 was CNY 61,772,280.35, down from CNY 71,542,748.02 in 2023, reflecting a decline of 13.5%[18] - Cash inflow from investment activities increased to CNY 1,894,755,034.93 in 2024, compared to CNY 1,808,046,369.72 in 2023, marking a growth of 4.8%[18] - Net cash flow from investment activities was negative CNY 487,435,499.57 in 2024, worsening from negative CNY 137,151,302.73 in 2023[18] Shareholder Information - The company has not reported any changes in major shareholders or their participation in securities lending activities[8] - The company has not disclosed any significant new strategies or product developments during the reporting period[9] - There are no applicable reminders for investors regarding the company's operational status during the reporting period[9] Equity and Dividends - The company implemented an equity incentive plan resulting in share-based payment expenses (after tax) of ¥946.25 million, leading to a 20.92% decline in net profit after adjustments[4] - The total equity attributable to shareholders was CNY 1,612,218,560.02, slightly down from CNY 1,626,755,218.95, indicating a decrease of 0.89%[13] - The ending cash and cash equivalents balance for 2024 was CNY 625,060,411.36, down from CNY 1,128,655,443.89 in 2023, a decrease of 44.6%[19] - The company reported a significant increase in cash paid for dividends and interest, totaling CNY 102,191,193.85 in 2024, compared to CNY 46,915,102.55 in 2023, an increase of 117.5%[19]
伟思医疗(688580) - 2024 Q3 - 季度财报